[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638934":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":24,"locations":34,"responsibleParty":59,"collaborators":62,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":23,"enrollmentInfo":77,"targetDuration":23,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":23,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cirrhotic","ACTIVE_COMPARATOR","Cirrhotic patients will begin at 300 Gy. Dose escalation will proceed in 100 Gy increments within each arm, with safety continuously evaluated by the Data Safety Monitoring Committee",[13],"Other: Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-cirrhotic","Non-cirrhotic patients will begin at a dose of 200 Gy. Dose escalation will proceed in 100 Gy increments within each arm, with safety continuously evaluated by the Data Safety Monitoring Committee.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres","The objective of this study is to define an optimal \"ablative dose\" range for Y90 Radiation Segmentectomy that achieves complete sectoral ablation detectable on dual contrast MRI and to determine whether this dose-response relationship differs between cirrhotic and non-cirrhotic patients.",[9,15],null,[25,30],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Andrew C Gordon, MD, PhD","CONTACT","(561)703-0134","andrew.gordon@nm.org",{"name":31,"role":27,"phone":32,"phoneExt":23,"email":33},"Cameron Khakpour, BA","312-926-5509","cameron.khakpour@northwestern.edu",[35],{"facility":5,"status":23,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Chicago","Illinois","60611","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-87.65005,41.85003,{"lat":45,"lon":44},[48,49,50,52,55,57],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":23,"email":33},{"name":26,"role":51,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"name":53,"role":54,"phone":23,"phoneExt":23,"email":23},"Robert J Lewandowski, MD, FSIR","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":23,"phoneExt":23,"email":23},"Amir A Borhani, MD",{"name":58,"role":54,"phone":23,"phoneExt":23,"email":23},"Saad E Abu Zahra, MD",{"type":51,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Andrew Gordon","Professor",[63,65],{"name":64,"class":6},"Radiological Society of North America",{"name":66,"class":6},"Robert H. Lurie Cancer Center","100638934","phase-2-defining-the-ablative-dose-for-y-90-tare-100638934",false,"NCT07586046","Defining the Ablative Dose for Y-90 TARE","A Prospective Dose-Escalation Study to Define an Ablative Dose of Yttrium-90 Transarterial Radioembolization Using Advanced Dosimetry and Functional MRI (MARGIN Study)","MARGIN","Inclusion Criteria:\n\n* Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.\n* Age ≥18 years.\n* Tumor size ≤5 cm requiring treatment of ≤2 Couinaud segments.\n* Child-Pugh class A or B liver function\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate organ and bone marrow function as defined below:\n* Leukocytes (WBC) ≥ 3,000\u002FmcL\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL\n* Hemoglobin ≥ 9 g\u002FdL\n* Platelets ≥ 50,000\u002FmcL\n* Total bilirubin ≤ 3.0 mg\u002FdL\n* AST ≤ 100 U\u002FL, ALT ≤ 120 U\u002FL\n* Creatinine ≤ 2.0 mg\u002FdL or estimated GFR ≥ 40 mL\u002Fmin\u002F1.73 m²\n* Ability to undergo imaging and laboratory evaluations required by the study.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Extrahepatic metastases.\n* Pregnant or breastfeeding individuals.\n* Tumors requiring treatment of more than two Couinaud segments.\n* Known hypersensitivity to gadolinium-based contrast agents.\n* Contraindications to MRI (e.g., incompatible pacemakers, claustrophobia unresponsive to sedation).\n* Coagulopathy or clinical instability precluding angiographic intervention.\n* Prisoners or individuals under legal custody.\n* Adults unable to consent.\n* Individuals under 18 years of age.","ALL","18 Years",{"count":78,"type":79},30,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.",[85],"HCC - Hepatocellular Carcinoma",[73,87,88,89],"HCC","Y90","Liver Cancer","NOT_YET_RECRUITING","2026-05-07",{"date":93,"type":94},"2026-05-14","ACTUAL",{"date":96,"type":79},"2026-05",{"date":98,"type":79},"2029-05",{"name":5,"class":6},1]